The short answer
Kava may add to cyclobenzaprine-related drowsiness or impairment. Review the product before co-use; an exact added risk or safe separation interval has not been established.
What this answer covers
Piper methysticum beverages and extracts; product strength varies.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- cyclobenzaprine
The alertness effects may overlap
Cyclobenzaprine labeling cautions that other CNS depressants can intensify its effects. Supplement guidance advises against combining this herb with sedating substances, supporting a conditional precaution.
A sleep-benefit result is not a safety result
A kava and valerian trial did not establish sleep or anxiety benefit. It did not test cyclobenzaprine, and the lack of benefit cannot establish absence of impairment.
Identify both products
Kava beverages and extracts differ in composition. Cyclobenzaprine swallowed and sublingual formulations also differ, and evidence does not define a safe kava dose across them.
Have co-use reviewed
Ask the prescriber before adding the herb and avoid driving while impaired. A short timing gap has not been shown to prevent additive effects. Seek urgent help for severe confusion, breathing difficulty or inability to wake.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-sedation precaution from exact current cyclobenzaprine labels and supplement guidance; no exact pair rate or proven spacing strategy.
- Exact scope
- Piper methysticum beverages and extracts; product strength varies. with Cyclobenzaprine21949 IN; hydrochloride swallowed IR/ER and sublingual products with formulation-specific indications.
- Medication form and route
- oral medication; sublingual medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonin-syndrome warnings; concomitant MAOIs and14days after stopping contraindicated.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not extended-release or sublingual dosing; supplement-specific risk unmeasured.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonergic precautions; MAOI contraindication.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Different release/directions from immediate-release and sublingual products.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS depression and serotonergic precautions; MAOI contraindication retained.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not swallowed-tablet dosing; sublingual product administration instructions are not a universal supplement-separation rule.
Source 4: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact cyclobenzaprine article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: 05cfabd195d041cc
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.